Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | 4-quinolones (quinolones). |
| Generic Name : | Ofloxacin |
| Drug description : | Tarivid: 200 mg off-white f-c oblong scored tablet marked MXI and logo; 400 mg yellow f-c oblong scored tablet. Tarivid Infusion: solution. |
| Presentation : | Tarivid: Ofloxacin 200mg , 400mg . Tarivid Infusion: Ofloxacin (as hydrochloride) 2 mg /mL. |
| Indications : | Tarivid: upper and lower urinary tract infections, lower respiratory tract infections, uncomplicated urethral and cervical gonorrhoea, non- gonococcal urethritis and cervicitis, skin and soft tissue infections. Tarivid Infusion: acute and chronic infections of the lower respiratory tract, acute and chronic upper and lower urinary tract infections, skin and soft tissue infections, septicaemia. Microbiological results indicate that the following organisms may be regarded as sensitive: Staphylococcus aureus (including methicillin resistant staphylococci), Staphylococcus epidermidis, Neisseria species, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Hafnia, Proteus (indole-negative and indole-positive), Salmonella, Shigella, Acinetobacter, Yersinia enterocolitica, Campylobacter jejuni, Aeromonas, Plesiomonas, Vibrio cholerae, Vibrio parahaemolyticus, Haemophilus influenzae, Chlamydiae, Legionella, Gardnerella.Variable Streptococci, Serrratia marcescens, Pseudomonas aeruginosa, Clostridium species and Mycoplasmas.Anaerobic bacteria are usually resistant. Tarivid is not normally active against Treponema pallidum. |
| Adult Dosage : | Tarivid: Depending on type and severity of infection, 200 - 800 mg once daily in the morning or larger doses in two divided doses. Lower UTI, 200 - 400 mg daily. Upper UTI, 200 - 400 mg daily, increasing to 400 mg twice daily if necessary. LRTI, 400 mg daily, increasing to 400 mg twice daily if necessary. Gonorrhoea, 400 mg as a single dose. NGU, 400 mg daily. Skin and soft tissue infections, 400 mg twice daily. Tarivid Infusion: Usually 200 - 800 mg daily by slow intravenous infusion over 30 minutes for 7 - 10 days depending on type and severity of infection. Complicated UTI, 200 mg daily. LRTI and septicaemia, 200 mg twice daily. Skin and soft tissue infections, 400 mg twice daily. |
| Child Dosage : | Not recommended. |
| Contra Indications : | History of epilepsy or tendinitis. Pregnancy, lactation. Growing adolescents. |
| Special Precautions : | Psychiatric disorders. Renal and hepatic impairment. Haemodialysis or peritoneal dialysis. 6-G-PD deficiency. Exposure to strong sunlight or UV rays. Driving or operating machinery. |
| Interactions : | Magnesium or aluminium antacids, sucralfate, glibenclamide, iron, probenecid, cimetidine, frusemide (furosemide), methotrexate, NSAIDs, anticoagulants. Injection: barbiturate anaesthetics, hypotensives. |
| Adverse Reactions : | GI upset, hypersensitivity reactions, skin reactions, convulsions, CNS disturbances, (discontinue if suspected). Transient increases in liver enzymes, disturbance of kidney function and blood sugars, porphyria, tachycardia, hypotension. Rarely, weakness, joint and muscle pain, tendonitis (discontinue treatment and rest limb), tendon rupture, bone marrow depression, acute interstitial nephritis, serum creatinine increase, cholestatic jaundice, hepatitis, severe liver damage, haematological disturbances. Injection: pain at injection site, thrombophlebitis. |
| Manufacturer : | Aventis |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org